Participant flow

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) · Source last updated 2016-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   etopodide, doxorubicin, cisplatin and mitotane Etoposide Doxorubicin Cisplatin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)

   id

   FG000

   title

   EDP-M

2. description

   streptozotocin and mitotane Streptozotocin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)

   id

   FG001

   title

   Sz-M

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         151

      2. group Id

         FG001

         num Subjects

         153

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         148

      2. group Id

         FG001

         num Subjects

         149

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         84

      2. group Id

         FG001

         num Subjects

         101

      type

      Received Second Line Therapy

   4. achievements

      1. group Id

         FG000

         num Subjects

         151

      2. group Id

         FG001

         num Subjects

         153

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice